Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients

Objective Coronavirus disease 2019 (COVID‐19) has progressed rapidly around the world, reaching a lethality of up to 20% due to acute respiratory distress syndrome (ARDS). This latter condition is a relevant concern for systemic lupus erythematosus (SLE); however, data on this topic are limited to f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Isabela Maria Bertoglio, Juliana Miranda de Lucena Valim, Danielle Daffre, Nádia Emi Aikawa, Clovis Artur Silva, Eloisa Bonfá, Michelle Remião Ugolini‐Lopes
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/32332e12575d431f8388e2518d097e48
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32332e12575d431f8388e2518d097e48
record_format	dspace
spelling	oai:doaj.org-article:32332e12575d431f8388e2518d097e482021-11-16T09:54:20ZPoor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients2578-574510.1002/acr2.11329https://doaj.org/article/32332e12575d431f8388e2518d097e482021-11-01T00:00:00Zhttps://doi.org/10.1002/acr2.11329https://doaj.org/toc/2578-5745Objective Coronavirus disease 2019 (COVID‐19) has progressed rapidly around the world, reaching a lethality of up to 20% due to acute respiratory distress syndrome (ARDS). This latter condition is a relevant concern for systemic lupus erythematosus (SLE); however, data on this topic are limited to few case series. Our objective was to evaluate in hospitalized patients with SLE and with COVID‐19–associated ARDS (confirmed by reverse transcription‐polymerase chain reaction) the risk of mortality and combined poor outcomes (death, intensive care unit [ICU] admission, and/or mechanical ventilation [MV] use) and to compare with that of patients without SLE. Methods This is a nationwide cross‐sectional study of patients with severe acute respiratory syndrome coronavirus 2 nested in the national Influenza Epidemiological Surveillance Information System (Sistema de Informação de Vigilância Epidemiológica da Gripe [SIVEP‐gripe]). Mortality rates, frequencies of ICU admissions, and MV use for 319 patients with SLE and 251 800 patients without SLE were calculated as well as relative risks (RRs). A fully adjusted multiple logistic regression was performed to adjust factors, such as age and well‐known comorbidities, that might impact worse outcomes. Results Patients with SLE had an increased risk of death and combined poor outcome compared with patients without SLE (RR = 1.738, 95% confidence interval [CI]: 1.557‐1.914, and RR = 1.391, 95% CI: 1.282‐1.492, respectively). Among all investigated comorbidities, SLE yielded the higher risk of death and combined poor outcomes (RR = 2.205, 95% CI: 1.780‐2.633, and RR = 1.654, 95% CI: 1.410‐1.88, respectively). Conclusions This study provides novel evidence that patients with SLE hospitalized because of COVID‐19 have significantly higher risks of death and poor outcomes compared with patients without comorbidities and patients with other comorbidities.Isabela Maria BertoglioJuliana Miranda de Lucena ValimDanielle DaffreNádia Emi AikawaClovis Artur SilvaEloisa BonfáMichelle Remião Ugolini‐LopesWileyarticleDiseases of the musculoskeletal systemRC925-935ENACR Open Rheumatology, Vol 3, Iss 11, Pp 804-811 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Isabela Maria Bertoglio Juliana Miranda de Lucena Valim Danielle Daffre Nádia Emi Aikawa Clovis Artur Silva Eloisa Bonfá Michelle Remião Ugolini‐Lopes Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
description	Objective Coronavirus disease 2019 (COVID‐19) has progressed rapidly around the world, reaching a lethality of up to 20% due to acute respiratory distress syndrome (ARDS). This latter condition is a relevant concern for systemic lupus erythematosus (SLE); however, data on this topic are limited to few case series. Our objective was to evaluate in hospitalized patients with SLE and with COVID‐19–associated ARDS (confirmed by reverse transcription‐polymerase chain reaction) the risk of mortality and combined poor outcomes (death, intensive care unit [ICU] admission, and/or mechanical ventilation [MV] use) and to compare with that of patients without SLE. Methods This is a nationwide cross‐sectional study of patients with severe acute respiratory syndrome coronavirus 2 nested in the national Influenza Epidemiological Surveillance Information System (Sistema de Informação de Vigilância Epidemiológica da Gripe [SIVEP‐gripe]). Mortality rates, frequencies of ICU admissions, and MV use for 319 patients with SLE and 251 800 patients without SLE were calculated as well as relative risks (RRs). A fully adjusted multiple logistic regression was performed to adjust factors, such as age and well‐known comorbidities, that might impact worse outcomes. Results Patients with SLE had an increased risk of death and combined poor outcome compared with patients without SLE (RR = 1.738, 95% confidence interval [CI]: 1.557‐1.914, and RR = 1.391, 95% CI: 1.282‐1.492, respectively). Among all investigated comorbidities, SLE yielded the higher risk of death and combined poor outcomes (RR = 2.205, 95% CI: 1.780‐2.633, and RR = 1.654, 95% CI: 1.410‐1.88, respectively). Conclusions This study provides novel evidence that patients with SLE hospitalized because of COVID‐19 have significantly higher risks of death and poor outcomes compared with patients without comorbidities and patients with other comorbidities.
format	article
author	Isabela Maria Bertoglio Juliana Miranda de Lucena Valim Danielle Daffre Nádia Emi Aikawa Clovis Artur Silva Eloisa Bonfá Michelle Remião Ugolini‐Lopes
author_facet	Isabela Maria Bertoglio Juliana Miranda de Lucena Valim Danielle Daffre Nádia Emi Aikawa Clovis Artur Silva Eloisa Bonfá Michelle Remião Ugolini‐Lopes
author_sort	Isabela Maria Bertoglio
title	Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
title_short	Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
title_full	Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
title_fullStr	Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
title_full_unstemmed	Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
title_sort	poor prognosis of covid‐19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross‐sectional population study of 252 119 patients
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/32332e12575d431f8388e2518d097e48
work_keys_str_mv	AT isabelamariabertoglio poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients AT julianamirandadelucenavalim poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients AT danielledaffre poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients AT nadiaemiaikawa poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients AT clovisartursilva poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients AT eloisabonfa poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients AT michelleremiaougolinilopes poorprognosisofcovid19acuterespiratorydistresssyndromeinlupuserythematosusnationwidecrosssectionalpopulationstudyof252119patients
_version_	1718426595998302208

Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients

Ejemplares similares